🚀Enjoy a 7-Day Free Trial Until Jul 19, 2024!

IN

IN8BIO, Inc.NASDAQ INAB Stock Report

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is INAB undervalued compared to its fair value?

The fair value of INAB stock is hidden USD. Relative to the market price of 0.878 USD IN8BIO, Inc. is hidden.

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Its lead product candida...[More about valuation]

IN8BIO, . Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.037 $B

Price:

0.878 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.227

FINANCIALS

IN8BIO, . financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0072 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0072 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.026 B
0.018 B

Financial Position Analysis

Assets

0.026 B
Current Assets
0.017 B
Total non-current assets
0.0097 B

Total current liabilities
0.0047 B
Total non-current liabilities
0.0038 B

Cash Flow Statement

-0.006 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0057 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

IN8BIO, . fundamental analysis for trailing twelve months (TTM)

Profitability score


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is INAB attractive for investment based on fundamental analysis?

INAB stock rating is hidden. IN8BIO, . is a hidden by Eyestock methodology.

Get INAB Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

INAB analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for INAB to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

IN8BIO, Inc. competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

IN8BIO, Inc. dividends

INAB dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About INAB stock

About the company IN8BIO, Inc.

Market cap $B

0.037

Dividend yield

Shares outstanding

24.5022 B

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Its lead product candidates are in phase I clinical trials. Its lead product candidate, INB-200, is for the treatment of patients with newly diagnosed glioblastoma (GBM), and INB-100, for the treatment of patients with leukemia that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company's DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-400, focused on addressing GBM and other solid tumor types. Its DeltEx platform has enabled a pipeline of preclinical and clinical product candidates, which are designed to target and potentially eradicate disease, to improve patient outcomes. Its platform is designed to overcome various challenges associated with expansion, genetic engineering and manufacturing of gamma-delta T cells.

INAB profile

  • Ticker

    INAB

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    12 November 2020

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    19

  • City

    New York City

  • Address

    Empire State Building, 350 5Th Avenue, Suite 5330

  • Cusip

    45674E109